Summary & Overview

Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

DRG 659 encompasses inpatient kidney and ureter procedures for non-neoplastic conditions accompanied by a Major Complication or Comorbidity, reflecting higher clinical complexity. It matters for inpatient reimbursement because the Major Complication or Comorbidity elevates resource intensity and influences the Medicare payment weight for the stay.

Kidney and Ureter Procedures for Non-Neoplasm with MCCDRG Kidney and Ureter Procedures for Non-Neoplasm with MCCDRG 659Diagnosis-Related GroupInpatient ReimbursementMedicareUrologyNephrologySurgical ProceduresHospital Coding

DRG 659 Overview

DRG 659 covers inpatient admissions for kidney and ureter surgical procedures related to non-neoplastic conditions when a Major Complication or Comorbidity is present. Typical cases include complex stone disease, obstructive uropathy, infection with sepsis, or traumatic injury requiring operative intervention and intensive care. This Diagnosis-Related Group matters for Medicare payment because the presence of a Major Complication or Comorbidity increases resource use and raises the relative payment weight. Hospitals and coders must accurately capture operative codes and comorbid conditions to ensure appropriate Medicare reimbursement.

Clinical Trials

Acute perioperative intervention trials evaluating optimization of surgical techniques, perioperative hemodynamic protocols, or novel minimally invasive approaches for complex kidney and ureter procedures in non-neoplastic disease with major complications or comorbidities. These studies enroll inpatient adults undergoing nephrectomy, partial nephrectomy, ureteral reconstruction, or stone-related surgeries who have significant physiologic compromise (for example sepsis, acute kidney injury, or cardiorespiratory instability) to test strategies that reduce intraoperative blood loss, transfusion needs, or immediate postoperative organ dysfunction. Findings directly inform surgeons and hospitalists about practices that can shorten ICU stays, lower complication rates, and reduce high-cost resource utilization that drives reimbursements for this high-MCC DRG.
Comparative effectiveness studies comparing approaches to managing severe non-neoplastic renal/ureteral conditions (such as obstructing stones with infection, complicated pyelonephritis requiring drainage, or ischemic/traumatic kidney injury) that examine outcomes of endoscopic decompression versus open or percutaneous approaches, timing of definitive reconstruction, or different antimicrobial/adjunctive care bundles. These trials typically include heterogeneous inpatient populations with comorbid chronic kidney disease or sepsis who are at elevated risk of prolonged hospitalization and readmission; they measure clinical endpoints like renal recovery, need for repeat procedures, length of stay, and complication rates. Results are relevant to payers and hospital administrators because they help determine cost-effective care pathways and appropriate utilization of high-cost procedures and postoperative resources for patients assigned to this DRG.
Post-discharge and outcomes research focused on renal function trajectory and readmission prevention after hospitalization for kidney and ureter procedures complicated by major comorbid conditions, assessing interventions such as structured transitional care, early nephrology follow-up, remote monitoring of renal function, or care coordination for patients with baseline CKD. These cohort or pragmatic randomized studies enroll survivors of index admission who are at risk for progressive chronic kidney disease, recurrent urinary tract infections, or device-related complications, and track 30- to 365-day outcomes including readmissions, dialysis initiation, and functional status. This research informs quality improvement, case management, and value-based payment strategies by identifying interventions that reduce costly readmissions and long-term dialysis dependence among patients in this high-acuity DRG.

Clinical Trials

Acute perioperative intervention trials evaluating optimization of surgical techniques, perioperative hemodynamic protocols, or novel minimally invasive approaches for complex kidney and ureter procedures in non-neoplastic disease with major complications or comorbidities. These studies enroll inpatient adults undergoing nephrectomy, partial nephrectomy, ureteral reconstruction, or stone-related surgeries who have significant physiologic compromise (for example sepsis, acute kidney injury, or cardiorespiratory instability) to test strategies that reduce intraoperative blood loss, transfusion needs, or immediate postoperative organ dysfunction. Findings directly inform surgeons and hospitalists about practices that can shorten ICU stays, lower complication rates, and reduce high-cost resource utilization that drives reimbursements for this high-MCC DRG.
Comparative effectiveness studies comparing approaches to managing severe non-neoplastic renal/ureteral conditions (such as obstructing stones with infection, complicated pyelonephritis requiring drainage, or ischemic/traumatic kidney injury) that examine outcomes of endoscopic decompression versus open or percutaneous approaches, timing of definitive reconstruction, or different antimicrobial/adjunctive care bundles. These trials typically include heterogeneous inpatient populations with comorbid chronic kidney disease or sepsis who are at elevated risk of prolonged hospitalization and readmission; they measure clinical endpoints like renal recovery, need for repeat procedures, length of stay, and complication rates. Results are relevant to payers and hospital administrators because they help determine cost-effective care pathways and appropriate utilization of high-cost procedures and postoperative resources for patients assigned to this DRG.
Post-discharge and outcomes research focused on renal function trajectory and readmission prevention after hospitalization for kidney and ureter procedures complicated by major comorbid conditions, assessing interventions such as structured transitional care, early nephrology follow-up, remote monitoring of renal function, or care coordination for patients with baseline CKD. These cohort or pragmatic randomized studies enroll survivors of index admission who are at risk for progressive chronic kidney disease, recurrent urinary tract infections, or device-related complications, and track 30- to 365-day outcomes including readmissions, dialysis initiation, and functional status. This research informs quality improvement, case management, and value-based payment strategies by identifying interventions that reduce costly readmissions and long-term dialysis dependence among patients in this high-acuity DRG.

OpenPayer

Summary & Overview

Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

DRG 659 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes